CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...